Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 31

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
2024.

Six months ended June 30, 2025 and 2024

Revenue

We had no revenue during the six months ended June 30, 2025 and 2024.     

Cost of Goods Sold     

We had no cost of goods sold during the six months ended June 30, 2025 and 2024.     

Research and Development     

Research and development expenses were $909,746 for the six months ended June 30, 2025, as compared to $1,757,892 for the six months ended June 30, 2024, a decrease of $848,416, or 48%. The costs include primarily wages, fees, equipment and third-party costs for the development of our TAEUS product line. Research and development expenses decreased from the prior year as we completed development of our initial TAEUS product and began focusing our spending on clinical trials and commercialization of the product that has been developed.

 20Table of Contents

Sales and Marketing     

Sales and marketing expenses were $137,825 for the six months ended June 30, 2025, as compared to $401,612  for the six months ended June 30, 2024, a decrease of $263,787, or 66%. The costs include primarily headcount and pre-selling activities for our TAEUS product line. Sales and marketing expenses decreased largely due to our restructuring in the second quarter of 2024. Currently, our marketing efforts are through our website and attendance of key industry meetings.

General and Administrative     

Our general and administrative expenses for the six months ended June 30, 2025 were $1,722,801, compared to $2,851,890 for the six months ended June 30, 2024, a decrease of $1,129,089, or 40%. Our wage and related expenses for the six months ended June 30, 2025 were $482,576, compared to $1,222,478 for the six months ended June 30, 2024. Wage and related expenses in the six months ended June 30, 2025 included $151,551 of stock compensation expense related to the issuance and vesting of options and RSUs for the three months ended June 30, 2025. Our professional fees, which include legal, audit, and investor relations, for the six months ended June 30, 2025 were $719,815, compared to